Cubist’s Zerbaxa Approval Marks Firm’s Second Novel Antibiotic In 2014
With only two weeks left in 2014, Cubist grabs another FDA approval for an antibiotic, this time to treat Gram-negative infections.
With only two weeks left in 2014, Cubist grabs another FDA approval for an antibiotic, this time to treat Gram-negative infections.